The BioVentures Institute Sp. z o.o. is an innovation-driven molecular biotechnology company, conducting applied research, product development and production, utilizing advanced genetic engineering, molecular biology, biochemical and microbiological technologies. Our proprietary universal recombinant DNA, RNA, protein technology for the construction of a new generation vaccines, biologics, biosymilars, industrial and environmental processes is protected worldwide by 5 patents and 6 patent applications. This break-through biotechnology of ordered DNA fragment amplification-expression and construction of genetically programmable artificial RNA and proteins provides scientific and economical solutions, not possible with other known technologies.


BioVentures Institute mission:

research-oriented molecular biotechnology company, aiming at improving life quality by providing novel medical, industrial and environmental biomolecular technologies to create better us and better world.

Kobieta naukowiec
business Man

Business scope:

developing and applying advanced novel genetic engineering technologies for medical, research, industrial end environmental applications. Cloning and production of recombinant proteins. Contract research.

Our leading edge technology:

DNA fragment amplification-expression method for construction of concatemeric nucleic acids, proteins, bionanostructures with genetically programmable functions. This is a universal recombinant DNA technology for creation of a new generation vaccines, biologics, biosymilars, industrial bioprocesses and environmental detoxification, which is globally protected by patents and patent applications.


Research Team

Piotr Skowron, Ph.D., D.Sc., Professor

Professor of molecular biology,  founder and Head of Molecular Biotechnology Department at University of Gdansk (Poland). His Ph.D. was a joint project of the Department of Oncology, University of Wisconsin-Madison (USA) and University of Gdansk. Scientist and inventor, for over 25 years engaged in research in the areas of molecular biology of bacteria, thermophilic microorganisms, regenerative medicine, anti-cancer therapies, as well as the development of novel gene cloning, manipulation and expression technologies, protein engineering and biosynthesis. Co-author of high level publications (+60, IF +210, cit. +500), 28 patents and patent applications. Principal founder, CEO and an author of BioVentures Institute Ltd. biotechnology -  DNA Fragment Amplification & Concatemeric Proteins Construction - a technology for the construction of artificial, concatemeric DNA, RNA and proteins with programmable functions. Co-founder of 9 biotechnology start-up companies. Extensive industrial experience: developed over 70 original biotechnology methods and products, an original inventor of DNA micro-spin/silica purification format (world sales +500 mln USD/year), for 13 years head investigator and director of R&D at USA biotechnology companies, received 1st award (2015) from the Pomeranian Employers Association in the category ‘Primum Cooperatio’ that is ‘first and foremost cooperation’ – ‘proving that cooperation of scientific and economic environment brings tangible benefits to business and science.’ Received four awards from th Chairman of the University of Gdansk for scientific achievements and numerous grants, industrial and academic, for a total of more than 17 mln USD. Conducts worldwide scientific collaborations.

Grzegorz Węgrzyn, Ph.D., D.Sc., Professor

Graduated from University of Gdansk, Poland. In 1987 he obtained MSc degree in biology, and in 1991 PhD degree in molecular genetics. His PhD thesis was focused on the regulation of DNA replication in starved cells. Then (in 1991), he was a research fellow at the Department of Biochemistry, University of Nottingham Medical School (UK), where he worked on the mechanisms of gene expression regulation in bacteria. In 1992 he was a post-doctoral researcher at Center for Molecular Genetics, University of California at San Diego (USA), where he investigated regulation of viral DNA replication. Since 1996 he is a head of Department of Molecular Biology at the University of Gdansk (Poland). In his laboratory, several projects are conducted, which are focused mainly on regulation of gene expression and DNA replication and mechanisms and new treatment methods of human genetic diseases. Grzegorz Wegrzyn is a co-author of over 400 scientific articles in peer-reviewed journals and over 600 communications on scientific conferences. He is a member of American Society for Biochemistry and Molecular Biology, American Society for Microbiology and International Society for Plasmid Biology. He is an editor of several scientific journals, including FEMS Microbiology Reviews, Microbial Cell Factories (Editor-in-Chief), Metabolic Brain Disease (Deputy-Chief-Editor), Plasmid, Scientific Reports, and Acta Biochimica Polonica (Editor-in-Chief). He supervised 52 PhD theses and has experience in leading teams, having functions of Head of Department of Molecular Biology, Dean of Faculty (2002-2008), and Vice-Rector for Research (2008-2016).

Alicja Wiercińska-Drapało, Ph.D., Professor

Worldwide recognized specialist in hepatology and AIDS, head of the Hepatology and AIDS Clinic in Warsaw, Poland. Head of Counseling for HIV-infected and AIDS patients, sept. of Bowel Diseases at the Medical University in Bialystok, Poland. Expert reviewing over 300 publications in peer reviewed international scientific journals and grant applications. Editorial head of HIV & AIDS Review, member of the Committee of Editors of the following international journals: Recent Patents on Endocrine Metabolic and Immune Drug Discovery, The Open Infectious Desease Journal. Awarded by the Minister of Health for scientific achievements in 2006, 2007, 2008 and for the contribution to the case of AIDS patients in 2008, 2009, 2010. Major contributor to studies on co-infection of HBV and HCV with HIV, the interdependence of the development of AIDS and the response to HAART therapy, the evaluation of new biomarkers in assessing the severity of clinical inflammatory bowel diseases, organ complications in HIV-infected patients undergoing antiretroviral therapy, new biomarkers for the cancer diagnosis in HIV-infected patients. Impact Factor app. 120; Index H = 8.

Łukasz Janus, Ph.D.

Graduated from Poznan University of Life Sciences and the Adam Mickiewicz University in Poznan, Poland. PhD defended in 2012 in the discipline of plant biotechnology. Łukasz Janus is passionate about applying new technologies in biotechnology as well as medical and cosmetic chemistry. Co-author of publications in international journals (IF 25.4) as well as co-author of patents in national and international procedures (including P407950, PCT / IB2015 / 052915, WO / 2015/162560). Co-founder of 9 bio-medical companies. In the years 2009-2020, he participated in 10 grant projects in the filed of biotechnology and medical devices (including NCBiR Strategmed project in regnerative medicine, NCBiR project POIG 1.4, NCBiR project 3.1 POIG). Winner of 4 competitions in commercialization of scientific products and 3 prizes at biotechnology conferences. For achievements in the field of combining scientific work with effective commercialization of scientific research, Łukasz Janus was nominated for the Man of the Year 2012 title.

Ireneusz Sobolewski, Ph.D.

Obtained his master's degree in 1998 at the Faculty of Chemistry, University of Gdansk. The mainstream of interest was focused on research on complex compounds of transition metal cations with carbohydrates. He was ecologically committed, he cooperated with the ecological monthly EkoBałtyk, writing popular science articles on the subject of chemistry. Developing his interests related to the chemistry of nucleic acids, in 2016 he obtained a doctorate in chemical sciences in the field of biochemistry. 20 years of experience in the biotechnology industry (1999 - 2019) as a chemist, head of the isotope and DNA sequencing laboratory, general manager of the production of reagents used in molecular biology - kits for the isolation of nucleic acids. Development of a new product line - over 20 specialized kits designed to isolate RNA, DNA and proteins from various sources. Significant participation in genetic engineering projects involving cloning of bacterial, viral and human genes. Implementation of the task under the grant on a new anti-cancer therapy, managed by the Gdańsk University of Technology as part of the consortium TARGETTELO. NCBR STRATEGMED3/306853/9/NCBR/2017 (acronym TARGETTELO) (2017-2020). Implementation of the task under the grant TECHMATSTRATEG2/410747/11/NCBR/2019 (acronym BIONANOVA) (2019-2023).